<DOC>
	<DOCNO>NCT01258673</DOCNO>
	<brief_summary>The purpose study evaluate antihypertensive efficacy safety Fimasartan/Hydrochlorothiazide combination 60/12.5mg~120/12.5mg patient essential hypertension control fimasartan 60mg .</brief_summary>
	<brief_title>A Clinical Study Evaluate Efficacy Safety Fimasartan/Hydrochlorothiazide Combination-therapy</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Male female outpatient 18 year age old Patients antihypertensive agent screen : DBP &lt; 110mmHg Patients without antihypertensive agent screen : DBP 90mmHg~120mmHg Subjects agree participate sudy give write informed consent Subjects consider understand study , cooperative , able followedup end study Patients control blood pressure baseline visit , fimasartan 60mg 4weeks treatment , DBP 90mmHg~109mmHg SBP &lt; 180mmHg The sit DBP 120mmHg severe hypertensive patient sit systolic blood pressure 200mmHg Patients secondary hypertension Patients measure mean difference mean blood pressure SiDBP 10mmHg SiSBP 20mmHg screen baseline visit Patients severe renal ( Creatinine 1.5 time upper limit normal ) , gastrointestinal , hematological hepatic ( AST , ALT 2 twice upper limit normal ) disease etc . might affect absorption , disposition , metabolism excretion drug Patients postural hypotension Patients sever insulin dependent diabetes mellitus uncontrolled diabetes mellitus ( HbA1c &gt; 9 % , regimen change oral hypoglycemic agent within 12weeks , treat insulin screen ) Patients history myocardial infarction , severe coronary artery disease clinically significant heart failure valvular defect last 6 month Patients consumptive disease , autoimmune disease , connective tissue disease Patients history type B C hepatitis ( include carrier ) Patients HIV hepatitis Patients clinically significant laboratory abnormality Patients receive drug know affect blood pressure medical treatment influence blood pressure Patients allergy contraindication angiotensin II receptor antagonist Female childbearing potential undergo hysterectomy postmenopausal Patients judge history alcohol drug abuse investigator Patients participate clinical trial 12 week Screening Patients judge inappropriate study investigator reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Fimasartan</keyword>
	<keyword>Fimasartan/Hydrochlorothiazide combination</keyword>
</DOC>